Martin Harp
Associate Editor at Modern Retina
Associate Editor at Ophthalmology Times
Associate Editor at Optometry Times
Writer on the webs | Former Co-Host @gimmickpod | Music Snob | Movie Buff | Video Game Nerd | Wrestling Fan | Sports Enthusiast
Articles
-
1 week ago |
modernretina.com | Martin Harp
June 20, 2025The phase 2/3 clinical trial for OCU410ST will enroll 51 participants diagnosed with Stargardt disease. Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to begin a phase 2/3 pivotal confirmatory trial of OCU410ST. OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.
-
1 week ago |
modernretina.com | Martin Harp
Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE. The company has submitted the results to the Central Drugs Standard Control Organisation (CDSCO), India's national regulatory body for cosmetics, pharmaceuticals, and medical devices, for permission to start phase 2 of the study.
-
1 week ago |
ophthalmologytimes.com | Arshad Khanani |Sydney M Crago |Martin Harp
Author(s):,Arshad Khanani, MD, MA, FASRS, discussed the upcoming Clinical Trials Summit (CTS) 2025 meeting, which has become a key event in the ophthalmology and retina research calendar. This fifth-year anniversary meeting marks a notable expansion, with increased participation from clinicians, researchers, investors, venture capitalists, and Contract Research Organizations (CROs).
-
1 week ago |
europe.ophthalmologytimes.com | Martin Harp
Johnson & Johnson has launched TECNIS Odyssey IOL in Europe, the Middle East, and Canada. The TECNIS Odyssey IOL was first launched in the US in October 2024.1,2The TECNIS Odyssey IOL is a full vision range intraocular lens (IOL), built on the TECNIS platform from Johnson & Johnson, which, according to the company,1 provides 2 times better contrast in low lighting than PanOptix.
-
1 week ago |
ophthalmologytimes.com | Martin Harp
Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE. The company has submitted the results to the Central Drugs Standard Control Organisation (CDSCO), India's national regulatory body for cosmetics, pharmaceuticals, and medical devices, for permission to start phase 2 of the study.
Journalists covering the same region
Francisco Javier Diaz
Reporter at El Nuevo Día
Francisco Javier Diaz primarily covers news in San Juan, Puerto Rico and surrounding areas.
Melissa Alvarado Sierra
Freelance Writer at Freelance
Melissa Alvarado Sierra primarily covers news in Ponce, Puerto Rico, United States and surrounding areas.
Mivette Vega
Staff Reporter at Floricua
Staff Reporter at The Americano
Mivette Vega primarily covers news in Puerto Rico, including areas around San Juan and Ponce.
Andrew Tran
Investigative Data Reporter at The Washington Post
Andrew Tran primarily covers news in Washington, D.C., United States and surrounding areas.
Marjorie Ramírez
Breaking News Reporter at Telemundo PR
Marjorie Ramírez primarily covers news in Puerto Rico, particularly around the San Juan area and surrounding regions.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 252
- Tweets
- 19K
- DMs Open
- Yes